Sana Biotechnology (SANA) reported Tuesday "positive" initial results from a study that transplanted islet cells into a person with type 1 diabetes without the use of immunosuppression.
Sana shares were rising 225% in recent after-hours trading.
The study showed that the company's hypoimmune, or HIP, technology enabled the transplanted islet cells to avoid rejection and produce insulin without immunosuppression, the company said.
"Results of the study at four weeks after cell transplantation demonstrate the survival and function of pancreatic beta cells as measured by the presence of circulating C-peptide, a biomarker indicating that transplanted beta cells are producing insulin," Sana said.
The study didn't identify any safety issues, the company said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。